AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...

A recent study has shown that one dose of Bavarian Nordic’s Jynneos vaccine was overall 58% effective at preventing mpox ...

Three patients living with hypertrophic cardiomyopathy have had their disease classification downgraded following a single ...

IgniteData has announced a partnership with AstraZeneca, MSK for launching the Archer tool for automation of EHR-to-EDC in a ...

Corcept's Phase III trial of relacorilant with nab-paclitaxel has met its primary endpoint, demonstrating an improvement in ...

The therapeutic approach was safe, but the study did not meet its primary efficacy outcome using the six-minute walking test.

Vaxcyte is awaiting data from another vaccine candidate for invasive pneumococcal disease (IPD) before advancing to Phase III.

The primary endpoint of the dose-finding trial sought to measure the effect of different doses of AZD0780 given once daily across differing levels of LDL-C in patients. Credit: Shutterstock / Explode.

Results from the company’s trial of 3,500 patients found that disease burden was higher in men but women were at higher risk of MACE.

The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results were ...